Abstract

A 45-year-old male presented to our clinic with complaining of hematuria for a month. The investigations showed a 59 × 24-mm myxoid mass on the right lateral bladder wall and this was removed with transurethral resection. The histopathology evaluation result was seminoma (classic type). The medical history revealed that the patient had undergone inguinal orchiectomy for a testis tumour 10 years before and the diagnosis was classic type seminoma. He received chemotherapy following the orchiectomy, but had not gone for follow-up after the first year. There was no other metastasis and he was put on the iphosphamide, etoposide, cisplatin (IPE) protocol. The patient has been disease-free for the last 5 months and the tumour markers and cystoscopy were normal. Testis tumours can rarely cause other organ metastases in the late stage even if curative surgery and chemo-radiotherapy were initially administered. Proper follow-up is crucial. It is also necessary to query the tumour history when a tumour in any organ is considered.

Case report

A 45-year-old male with a 1-month history of hematuria presented to our clinic. His history revealed that he had undergone orchiectomy for a testis tumour (Stage: 1A) 10 years ago. The pathology was classic type testicular seminoma and he received 3 cycles of BEP (bleomycin, etoposide, cisplatin) postoperatively, but did not attend follow-up 1 year later. Physical examination revealed a right inguinal incision and normal left testis. Serum biochemistry and tumour marker results were within normal limits, with an alpha-fetoprotein (AFP) level of 3.5 ng/dL, beta-human chorionic gonadotropin (B-HCG) level of 1.2 ng/dL, and lactate dehydrogenase (LDH) level of 180 IU/L. Ultrasonography (USG) showed a 60 × 25-mm polypoid mass on the right lateral bladder wall. Abdominal tomography showed a 59 × 24-mm polypoid mass extending to the lumen on the right inferolateral bladder wall. Abdominal tomography showed a 59 × 24-mm polypoid mass extending to the lumen on the right inferolateral bladder wall with no other pathological finding (Fig. 1).

The right lateral bladder wall polypoid mass was resected under general anesthesia. No other bladder tumour was seen. Histopathology evaluation showed pleomorphic tumour cells with a hyperchromatic nucleus and a one-by-one arrangement infiltrating the bladder wall. There was widespread necrosis and occasional lymphocytes (Fig. 2).

Immunohistochemical investigations to show tumour infiltration revealed that the atypical cells were pan cytokeratin focal (+) (Fig. 3), vimentin (+), SMA (-), myoglobin (+), S-100 (-), CD34 (-), EMA (-), synaptophysin (-), and chromogranin (-). Morphological and immunohistochemical staining features suggested a malignant tumour infiltrating the bladder wall, but a definite diagnosis that required a repeat biopsy and an evaluation of the tissue paraffin blocks at the external centre. Immunohistochemical studies at the external center found diffuse and strong SALL4 and OCT3/4 expression leading to a diagnosis of bladder infiltration with classic type seminoma. Repeat transurethral resection was performed 4 weeks later and no tumour was seen on the evaluation of the specimen.

The patient was evaluated again for systemic metastases. F-18 Fluorodeoxyglucose (FDG) positron emission tomog-
(PET) was performed. There was a hypermetabolic FDG area on the right posterior bladder wall, but no other significant FDG involvement in the investigation area as regards metastatic malignancy.

The patient received 4 cycles of chemotherapy (ifosfamide 1200 mg/m², mesna 1200 mg/m², etoposide 75 mg/m², cisplatin 20 mg/m²) at 3-week intervals.

The urinalysis, hemogram, biochemistry values and tumour markers were normal on follow-up. Cystoscopy was normal, while PET investigation only showed metabolic regression of the hypermetabolic FDG involvement in the right posterior bladder wall seen at the previous investigation to a physiological level.

Discussion

Testis tumours are the most common malignant tumours in the 15 to 35 years age group in males and have an increasing full recovery rate thanks to the multimodal treatments being developed. The localization of the primary tumour, histological subgroups, whether the metastasis includes the lungs, and the AFP, B-HCG and LDH levels are important factors during the diagnosis and follow-up.

Urinary system metastasis is quite rare. Alsolama and colleagues reported on a case with concurrent bladder and testicular seminoma; Gürbüz and colleagues reported a case with simultaneous bladder carcinosarcoma and testis seminoma. Another case is present where orchiectomy was performed for testis seminoma and biopsy of the paraaortic and inguinal lymph nodes during a kidney transplant later on in this kidney recipient revealed seminoma again. The patient underwent radiotherapy and received immunosuppressives, but a bladder seminoma was found 3 years later. Another patient was diagnosed with extragonadal germ cell tumour with lymph node biopsy after retroperitoneal and cervical lymphadenopathy was detected. Chemotherapy was administered and the beta-HCG level increased during follow-up. The patient developed hematuria with bladder and right ureter metastasis followed by liver and mesenteric lymph node metastasis leading to his death. Another article reported a patient who underwent bilateral orchiectomy, retroperitoneal lymph node dissection, and chemotherapy for seminoma; the patient then developed a retrovesical 8 × 6 × 5-cm primary seminoma of the prostate 16 years later. Hashimoto and colleagues reported a primary seminoma involving the prostate. Khveekar and colleagues reported a case involving the prostate and bladder neck. Renal, adrenal gland, psoas muscle, gastric, seminal vesicle, bladder, prostate and pericardial involvement are very rare (<1%). Our literature search did not reveal any other classic type seminoma case that had metastasized only to the bladder 10 years later with no metastasis to the retroperitoneal region or other solid organs.
Late metastasis of testis seminoma to the bladder

Metastases within the first 2 years are considered early for testis tumours, while those after 5 years are considered late. Most metastases develop within the first 2 years. Follow-up after radiotherapy and chemotherapy is very important due to the risk of secondary malignancy development. The follow-up frequency varies depending on whether the prognosis is good, moderate or poor, but follow-up every 2 to 4 months for the first 3 years, every 6 months for the 4th to 7th year, and once a year for life afterwards is necessary.

Conclusion

Testis tumours should be followed up according to the guidelines. History should be carefully queried and the possibility of solid organ metastasis at the very late stage should always be considered. Treatment should then be planned accordingly.

Competing interests: The authors declare no competing financial or personal interests.

This paper has been peer-reviewed.

References


Correspondence: Dr. Ali Rıza Türkoglu, Şevket Yılmaz Educational and Research Hospital, Bursa, Turkey; a.turkoglu@hotmail.com